

**POWELL
GOLDSTEIN LLP**

Atlanta ■ Washington ■ Dallas

One Atlantic Center
Fourteenth Floor
1201 West Peachtree Street, NW
Atlanta, GA 30309-3488

Telephone: (404) 572-6600
Fax: (404) 572-6999
Internet: www.pogolaw.com

NOTICE: This communication may contain privileged or other confidential information. If you are not the intended recipient, or believe that you have received this communication in error, please do not print, copy, retransmit, disseminate, or otherwise use the information. Also, please indicate to the sender that you have received this communication in error, and delete the copy you received. Thank you.

FACSIMILE TRANSMISSION COVER SHEET

Date: March 14, 2007

To: Shelby Vigil Fax # 571-270-9987
PCT Operations

From: LuAnn K. Miller Recipient's Direct Dial # 703-308-9140
Sender's Direct Fax # 404-572-6999
Sender's e-mail address: lmiller@pogolaw.com
Sender's Direct Dial # 404-572-6624

Our File # 149459.00002 Attorney # 3456

Appl. # 10/596,797

Total Pages (Including This Page): 14
Please notify LuAnn Miller at (404) 572-6624 if all pages are not received properly

COMMENTS:

Dear Shelby:

As we discussed, attached please find our Transmittal Letter amending the Priority Claim and submitting the English Translation of International Application No. PCT/EP2004/010081 to which U.S. Patent Application No. 10/596,797 claims priority. I will call you tomorrow morning to make sure you received everything you need.

Thank you for your kind assistance today.

Sincerely,

LuAnn K. Miller
IP Patent Paralegal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Bodo Gerold et al.	Confirmation No.:	1514
Appln. No.:	10/596,797	Group Art Unit:	3738
Filed:	June 23, 2006	Examiner:	TBA
Title:	RADIO-OPAQUE MARKER FOR MEDICAL IMPLANTS	Atty. Docket No.:	149459.00002
		Customer No.:	25207

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL LETTER

Applicant respectfully requests that the Transmittal Letter originally filed electronically with the U.S. Patent Office for the above-identified application be amended as follows. The electronic Transmittal listed the International Application Number as PCT/US04/10081. The International Application Number should be PCT/EP2004/010081, and was correctly identified in the Declaration, the Preliminary Amendment, the Marked-Up Specification and the Substitute Specification.

Additionally, Applicant hereby submits the attached English Translation of International Application No. PCT/EP2004/010081 as requested by PCT Operations.

It is believed that no fees are due; however the Commissioner for Patents is authorized to charge any required fees to Deposit Account 50-1429.


Respectfully submitted,
POWELL GOLDSTEIN LLP


Jason A. Bernstein
Reg. No. 31,236

POWELL GOLDSTEIN LLP
One Atlantic Center, Fourteenth Floor
1201 West Peachtree Street, NW
Atlanta, Georgia 30309-3488
Tel: 404-572-6900 888891 581429 10596797
Fax: 404-572-69993 DA
E-Mail: jbernstein@pogolaw.com

Certificate of Facsimile Transmission

I hereby certify that this document is being transmitted by facsimile to (571) 270-9987 on March 14, 2007, and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature: 

Print Name: LuAnn K. Miller

Applicant: BIOTRONIK VI Patent AG
Date: May 2, 2006
Our Reference: 02.021P-WO/US

5

Radio-opaque marker for medical implants

The present invention relates to a radiopaque marker for medical implants and implants having markers of this type.

10

In modern medical technology, implants are used to a continuously increasing degree. The implants are used for supporting vessels, hollow viscera, and vascular systems (endovascular implants), for attaching and temporarily fixing tissue implants and tissue transplants, or even for orthopedic purposes, e.g., as nails, plates, or screws. Frequently, only a temporary support or holding function until completion of the healing process or stabilization of the tissue is required and/or desired. In order to avoid complications which result from the implants remaining permanently in the body, the implants must either be operatively removed again or they are made of a material which is gradually degraded in the body, i.e., is biodegradable. The number of biodegradable materials based on polymers or alloys is continuously growing, but in many areas of application, the mechanical properties of a metallic material are still indispensable. In practice, until now only a few metallic materials have proven themselves is biodegradable. At least metal alloys made of magnesium, iron, and tungsten have been suggested.

25

Inter alia, biodegradable magnesium alloys which are suitable for endovascular and orthopedic implants are known from EP 1 270 023. The alloys may contain up to less than 5 weight-percent rare earths.

30

However, most biodegradable alloys and polymers for medical implants known from the related art have the disadvantage that they are not detectable or are only detectable to an unsatisfactory extent in current x-ray methods. How-

- 2 -

ever, x-ray diagnosis is an important instrument for postoperative monitoring of the healing progress or for checking minimally invasive interventions. Thus, for example, stents have been placed in the coronary arteries during acute myocardial infarction treatment for some years. According to current methods, 5 a catheter which carries the stent in an unexpanded state is positioned in the area of the lesion of the coronary vessel wall. Subsequently, the stent expands either through self-expansive forces or through inflation of a balloon, in order to prevent obstruction of the vessel wall in the expanded state. The procedure of positioning and expanding the stent must be monitored continuously during 10 the procedure through interventional cardiology.

The x-ray visibility of an implant manufactured from a metallic or polymer material is a function of the thickness of the material and, in addition, of the linear extinction coefficient of the material. Iron as a component of medical 15 steels has a linear extinction coefficient of 15.2 KeV/cm, for example, which is typically already insufficient for a contrast-rich monitoring image with the filigree structures of stents. Furthermore, it is known that the linear extinction coefficient becomes greater with increasing atomic number in the periodic system. Thus, for example, gold has a linear extinction coefficient of 101 KeV/cm. 20

Providing implants with a coating, a strip, or a marker which is incorporated or 25 molded on in another way to improve the x-ray visibility is therefore known. Essentially the following points must be observed for the selection of the marker material:

25

- the marker metal is not to worsen the mechanical properties of implant, in particular by increasing the rigidity,
- the marker must be biocompatible, and

30

- the marker may not flake or crack off during the implantation, in particular during the expansion or placement of a stent.

02.021P-WO/US

- 3 -

Known marker methods provide attaching metal strips made of gold or other noble metals in specific areas of the stent, for example. Metal strips of this type may loosen, shift, or even fall off, however. A non-degradable marker made of a noble metal causes the expectation of the formation of a local element with the usually non-noble metals of the main body of implant, through which the marker itself may be resolved very rapidly from the structure. However, when the marker is dissolved very rapidly, this may also occur before the complete endothelialization; the marker may then float away and result in an embolization. Furthermore, there is the danger of abrasion of the intima during positioning of the implant.

With metal coating methods, radiopaque marking areas may be applied to the implants through chemical or physical vacuum deposition (CVD or PVD). Alternatively, methods such as ion beam assisted deposition (IBAD) and microfusion are suitable, using which very homogeneous coatings in the micrometer range are producible on the implant surface.

The application of marker layers and the positioning of marker elements on the implants made of biodegradable alloys or polymers is anything but trivial and typically requires individual tailoring of the material properties of the marker element to the further materials used in the implant and also adaptations in the design of the implant. Known attempted achievements of the object may therefore not be transferred without further steps to new materials, in particular the promising biodegradable alloys and polymers. Furthermore, the marker element itself is to be at least largely biodegradable or is at least to be converted into physiologically harmless components. These are understood as components which have dimensions significantly smaller than the dimensions of the marker before implantation, but which are not degraded further and are intercalated in the body in unchanged form.

The present invention is accordingly based on the object of providing an at least partially biodegradable marker having a sufficient x-ray visibility.

02.021P-WO/US

- 4 -

A further object of the present invention is to specify suitable implants for at least partially biodegradable markers.

According to a first aspect of the present invention, the object of interest is achieved by a radiopaque marker for medical implants containing

- 5 - 10 to 90 weight-percent of a biodegradable base component,
- 10 - 10 to 90 weight-percent of one or more radiopaque elements from the group I, Au, Ta, Y, Nb, Mo, Ru, Rh, Ba, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Hf, Ta, W, Re, Os, Ir, and Bi as marker components, and
- 15 - less than or equal to 10 weight-percent residual components,
- 20 the components cited adding up to 100 weight-percent. The proportions of the components are weighted in this case in such way that the marker is still at least partially biodegradable, but there is nonetheless adequate x-ray visibility at normal dimensioning of the medical implant.
- 25 Biodegradability in the meaning according to the present invention is understood as at least partial degradation of the marker in the living organism occurring over time due to chemical, thermal, oxidative, mechanical, or biological processes. The degradation relates at least to the base component of the marker. The marker component is either biodegradable in turn or is provided as a finely divided powder after complete degradation of the base component, which may be excreted from the body without problems or is intercalated in the tissue without noticeable further biological interaction. In other words, the possibly remaining nonbiodegradable components of the marker component do not form a closed structure per se, but rather disintegrate into smaller components. Therefore, the marker component is to be evaluated and adapted in this direction through in vitro degradation experiments if necessary.
- 30

02.021P-WO/US

- 5 -

A preferred embodiment of the marker is an alloy which particularly contains one or more biodegradable elements from the group magnesium, iron, or zinc as the base component. These of alloys offers the advantage above all that the material properties of alloys are clearly adapted to one another in comparison

5 to typical biodegradable alloys, in particular magnesium alloys. The manufacturing of implants having marker elements, which are based on a combination of typical biodegradable metallic alloys as the main body with the radiopaque alloy according to the present invention as the marker, is thus simplified. The phase boundary tensions which otherwise typically frequently occur precisely

10 at the phase boundaries between marker and main body of implant may be reduced because of the adaptation of the material properties. The formation of local elements in heterogeneous alloys between the often noble marker components and the non-noble base components represents a desired effect which accelerates the decomposition of the marker.

15 In an alternative embodiment to the above-mentioned alloy, the marker is a composite having a biodegradable alloy as the base component. The base component is again gradually degraded in the above-mentioned way, through which the marker loses its original mechanical integrity. The further components are either also resorbed or intercalated in particle form in the tissue.

20 Furthermore, is preferable for the biodegradable polymer of the composite to comprise hyaluronic acid, chitosan, and polylactides, the polymers cited being able to be provided as derivatives which may be derived from the basic structure if necessary. The polymers cited appear to be especially suitable, since

25 their in vitro degradation may be controlled through targeted derivatization, outstandingly good biocompatibility is provided, the processing may be performed according to known methods, and the degradation products at least partially exert a positive physiological effect on the surrounding tissue.

30 The term "base component" in the meaning of the present invention also includes any type of combination of the cited materials and further materials capable of biodegradation, of course. Thus, the base component may be a mixture of multiple biodegradable polymers and/or alloys. The shared feature

02.021P-WO/US

- 6 -

of all these conceivable base component is the absolutely required simultaneous presence of a marker component.

According to a preferred embodiment of the present invention, which may also be implemented in combination with the above-mentioned special embodiments of the marker as an alloy or composite, the marker component comprises one or more elements from the group I, Ta, Y, Ce, Nd, Sm, Gd, or Dy. The elements cited are distinguished by their outstanding biocompatibility, favorable linear extinction coefficient, and good availability. In particular, a marker component which entirely or at least 90 weight-percent or more of the marker component comprises tantalum is especially preferred. Tantalum has been shown to be especially biocompatible and easily processable and may particularly be a component of the marker in the form of extremely small metal balls having a diameter of a few micrometers. In addition, if Y, Ce, Nd, Sm, Gd, or Dy are used, magnesium alloys become more heat resistant and may be processed better. The elements Y and Nd have additionally shown in the effect of inhibiting the proliferation of smooth human muscle cells in initial cell culture experiments, so that the use of these elements appears especially advisable in connection with endovascular implants, such as coronary stents.

The proportion of the base component in the marker is preferably 30 to 70 weight-percent, in particular 40 to 60 weight-percent. In this way, an extensive disintegration of the marker may be ensured, but good x-ray visibility may additionally be ensured.

Furthermore, it is preferable for a proportion of the rare earth metals, including yttrium, as components of the marker component, to be not more than 20 weight-percent, in particular not more than 15 weight-percent, in the marker. In this way, it may be ensured that the toxicity at least partially existing at the higher doses of the metals cited cannot result in formation of necrosis in the surrounding tissue.

The residual components comprise inorganic or organic fillers, auxiliary materials, or residual materials, which are provided without restrictions of the func-

02.021P-WO/US

- 7 -

tionality of the marker, e.g., because of impurities of the starting materials, but also for improved processing of the individual components. The proportion of the residual components in the marker is preferably \leq 5 weight-percent, in particular \leq 1 weight-percent. It is conceivable for the residual component to 5 be a pharmacologically active ingredient which improves the tissue compatibility, for example.

According to a second aspect of the present invention, the object of interest is achieved by a self-biodegradable implant which contains at least one section 10 which comprises the marker according to the present invention. The main body of the implant is molded from a biodegradable material which is synthesized on the basis of a polymer or metal, for example. It is conceivable and especially preferable for the main body of implant to be produced entirely or in parts from the marker. Alternatively, the main body may be coated with the 15 marker. In the first variation, markers based on an alloy are preferred, since these frequently fulfill the mechanical requirements of the material better. An example of this is coronary stents made of biodegradable magnesium, iron, or tungsten compounds. In case of coating with the marker, coating thicknesses in the range from approximately 5 to 100 μm are preferred, since these ensure 20 adequate x-ray visibility, but do not restrict the functionality of the coated main body. According to an advantageous embodiment, the coating is only applied terminally to the implant, e.g., through coating using a mask.

The implant is preferably at least partially molded from a biodegradable magnesium alloy known from the related art. In this case, an alloy whose base 25 component is also magnesium is preferred as the marker. In this way, the material properties of the main body and of the marker are adapted to one another. Implants made of known magnesium alloys may therefore be coated especially well with the alloy of the marker according to the present invention 30 or may be implemented in molded partial areas. The material similarity increases the adhesion between the different alloys, so that flaking or cracking of the coating or a fracture along the phase boundaries between the marker alloy and the known magnesium alloys of the main body in the event of me-

02.021P-WO/US

- 8 -

mechanical strain is avoided. Because of the very similar properties, it is generally not necessary to rework a basic stent design for applying or introducing the marker alloy, for example.

5 The at least largely biodegradable implant is preferably an endovascular implant, in particular a stent or an occluder. Furthermore, the marker according to the present invention, in particular in the form of an alloy, is preferably used in orthopedic implants, such as nails, screws, clips, or alloplastic prostheses, such as anastomosis implants in the form of a small tube for connecting
10 two vessel ends.

The present invention is explained in greater detail in the following in exemplary embodiments.

15 A stent of typical construction having a main frame made of the biodegradable magnesium alloy WE43 (composition: Y 4.1 weight-percent; Nd 2.2 weight-percent; Zr 0.5 weight-percent; other < 0.4 weight-percent and remainder Mg) is bonded to a marker in different ways in the following.

20 According to a first variation, the marker comprises a coating deposited from a Mg/Y target through PVD. The Mg/Y target has a composition of approximately 85 weight-percent magnesium and 15 weight-percent yttrium, for example. Of course, the elements for the base and marker components may be varied depending on the desired composition of the marker to be deposited. Deposition methods of this type are well-known to those skilled in the art, so that more detailed description will be dispensed with. The deposition method is controlled in this case in such a way that an approximately 5 to 100 μm thick layer of the marker results. If desired, the deposition location may be locally delimited by focusing the material beam or masking, e.g., to produce a terminal circular
25 marker.

30

According to an alternative variation, the surface of implant may be covered by a composite made of a biodegradable polymer base component and a

02.021P-WO/US

- 9 -

marker component. This may be performed, for example, by adding tiny tantalum or gadolinium balls acting as marker components to a polymer, based on polymerized hyaluronic acid, acting as a base component. The resulting dispersion is subsequently applied to the implant through common immersion or spraying methods and dried. A weight of the dried polymerized hyaluronic acid to the weight of the tantalum or gadolinium balls is approximately 50-50, for example. The marker may be introduced in a locally delimited way, e.g., in cavities in the main body of implant provided for this purpose, or may cover the entire implant as a coating.

02.021P-WO/US

PAGE 11/14 * RCVD AT 3/14/2007 5:07:32 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/34 * DNIS:2709987 * CSID:4045726999 * DURATION (mm:ss):03:36

BEST AVAILABLE COPY